Inhibition of MiR-9-5p Suppresses Prostate Cancer Progress by Targeting StarD13

Overview

Journal Cell Mol Biol Lett

Publisher Biomed Central

Specialties Biochemistry
Cell Biology
Molecular Biology

Date 2019 Mar 23

PMID 30899277

Citations 42

Authors

Lin Chen

Weifeng Hu

Guohao Li

Yonglian Guo

Zhihua Wan

Jiajun Yu

Affiliations

Soon will be listed here.

Abstract

Background: This study aims to investigate the effects of inhibiting microRNA-9-5p (miR-9-5p) on the expression of StAR-related lipid transfer domain containing 13 (StarD13) and the progress of prostate cancer.

Methods: The mRNA expression levels of miR-9-5p and StarD13 were determined in several prostate cancer cell lines. We chose DU145 and PC-3 cells for further research. The CCK8 assay was used to measure the cell viability. The cell invasion and wound-healing assays were respectively applied to evaluate invasion and migration. The expression of E-cadherin (E-cad), N-cadherin (N-cad) and vimentin were measured via western blot. DU145 and PC-3 cells overexpressing StarD13 were generated to investigate the variation in proliferation, invasion and migration. A luciferase reporter assay was used to identify the target of miR-9-5p.

Results: Our results show that miR-9-5p was highly expressed and StarD13 was suppressed in prostate cancer cells. MiR-9-5p inhibition repressed the cells' viability, invasion and migration. It also increased the expression of E-cad and decreased that of N-cad and vimentin. StarD13 overexpression gave the same results as silencing of miR-9-5p: suppression of cell proliferation, invasion and migration. The bioinformatics analysis predicted StarD13 as a target gene of miR-9-5p. Quantitative RT-PCR, western blot analysis and the dual-luciferase reporter assay were employed to confirm the prediction.

Conclusion: Our results show that miR-9-5p plays a powerful role in the growth, invasion, migration and epithelial-mesenchymal transition (EMT) of prostate cancer cells by regulating StarD13. A therapeutic agent inhibiting miR-9-5p could act as a tumor suppressor for prostate cancer.

Citing Articles

Decoding the mysteries of prostate cancer via cutting-edge liquid biopsy-based urine exosomes profiling.

Sonar S J Liq Biopsy. 2025; 6:100162.

PMID: 40027312 PMC: 11863813. DOI: 10.1016/j.jlb.2024.100162.

MiRNA Profiling of Areca Nut-Induced Carcinogenesis in Head and Neck Cancer.

Huang H, Chang J, You G, Fu Y, Shen E, Huang Y Cancers (Basel). 2024; 16(21).

PMID: 39518147 PMC: 11545612. DOI: 10.3390/cancers16213710.

MicroRNA in prostate cancer: from biogenesis to applicative potential.

Luo X, Wen W BMC Urol. 2024; 24(1):244.

PMID: 39506720 PMC: 11539483. DOI: 10.1186/s12894-024-01634-1.

Pre-operative Neo-adjuvant Chemotherapy Related miRNAs as Key Regulators and Therapeutic Targets in Colorectal Cancer.

Yalav O, Sonmezler O, Erdogan K, Rencuzogullari A, Doran F, Bisgin A Curr Aging Sci. 2023; 17(1):49-57.

PMID: 37723961 DOI: 10.2174/1874609816666230816152744.

miR-9-5p expression is associated with vascular invasion and prognosis in hepatocellular carcinoma, and in vitro verification.

Chen Y, Xu H, Tang H, Li H, Zhang C, Jin S J Cancer Res Clin Oncol. 2023; 149(16):14657-14671.

PMID: 37584711 DOI: 10.1007/s00432-023-05257-1.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Ching Y, Wong C, Chan S, Leung T, Ng D, Jin D . Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma. J Biol Chem. 2003; 278(12):10824-30. DOI: 10.1074/jbc.M208310200. View

Holeiter G, Heering J, Erlmann P, Schmid S, Jahne R, Olayioye M . Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway. Cancer Res. 2008; 68(21):8743-51. DOI: 10.1158/0008-5472.CAN-08-0984. View

Ghasri P, Admani S, Petelin A, Zachary C . Treatment of actinic cheilitis using a 1,927-nm thulium fractional laser. Dermatol Surg. 2012; 38(3):504-7. DOI: 10.1111/j.1524-4725.2011.02262.x. View

El-Sitt S, Khalil B, Hanna S, El-Sabban M, Fakhreddine N, El-Sibai M . DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. Oncol Rep. 2012; 28(2):511-8. DOI: 10.3892/or.2012.1819. View

Quan J, Elhousiny M, Johnson N, Gao J . Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclasts. Clin Exp Metastasis. 2013; 30(5):659-70. PMC: 3663202. DOI: 10.1007/s10585-013-9570-0. View

Hanna S, Khalil B, Nasrallah A, Saykali B, Sobh R, Nasser S . StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion. Int J Oncol. 2014; 44(5):1499-511. PMC: 4027929. DOI: 10.3892/ijo.2014.2330. View

Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y . Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 2014; 36(2):719-27. DOI: 10.1007/s13277-014-2697-z. View

Fujii T, Shimada K, Tatsumi Y, Fujimoto K, Konishi N . Syndecan-1 responsive microRNA-126 and 149 regulate cell proliferation in prostate cancer. Biochem Biophys Res Commun. 2014; 456(1):183-9. DOI: 10.1016/j.bbrc.2014.11.056. View

10.

Siegel R, Miller K, Jemal A . Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30. DOI: 10.3322/caac.21332. View

11.

Li X, Zheng L, Zhang F, Hu J, Chou J, Liu Y . STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer. Oncotarget. 2016; 7(17):23197-211. PMC: 5029620. DOI: 10.18632/oncotarget.8099. View

12.

Chang S, He S, Qiu G, Lu J, Wang J, Liu J . MicroRNA-125b promotes invasion and metastasis of gastric cancer by targeting STARD13 and NEU1. Tumour Biol. 2016; 37(9):12141-12151. DOI: 10.1007/s13277-016-5094-y. View

13.

DIppolito E, Plantamura I, Bongiovanni L, Casalini P, Baroni S, Piovan C . miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. Cancer Res. 2016; 76(18):5562-72. DOI: 10.1158/0008-5472.CAN-16-0140. View

14.

Roese-Koerner B, Stappert L, Berger T, Braun N, Veltel M, Jungverdorben J . Reciprocal Regulation between Bifunctional miR-9/9(∗) and its Transcriptional Modulator Notch in Human Neural Stem Cell Self-Renewal and Differentiation. Stem Cell Reports. 2016; 7(2):207-19. PMC: 4982985. DOI: 10.1016/j.stemcr.2016.06.008. View

15.

Seashols-Williams S, Budd W, Clark G, Wu Q, Daniel R, Dragoescu E . miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis. PLoS One. 2016; 11(7):e0159601. PMC: 4957825. DOI: 10.1371/journal.pone.0159601. View

16.

Akaza H, Onozawa M, Hinotsu S . Prostate cancer trends in Asia. World J Urol. 2016; 35(6):859-865. DOI: 10.1007/s00345-016-1939-7. View

17.

Liang X, Li H, Fu D, Chong T, Wang Z, Li Z . MicroRNA-1297 inhibits prostate cancer cell proliferation and invasion by targeting the AEG-1/Wnt signaling pathway. Biochem Biophys Res Commun. 2016; 480(2):208-214. DOI: 10.1016/j.bbrc.2016.10.029. View

18.

Zhang H, Wang F, Hu Y . STARD13 promotes hepatocellular carcinoma apoptosis by acting as a ceRNA for Fas. Biotechnol Lett. 2016; 39(2):207-217. DOI: 10.1007/s10529-016-2253-6. View

19.

Shukla K, Misra S, Pareek P, Mishra V, Singhal B, Sharma P . Recent scenario of microRNA as diagnostic and prognostic biomarkers of prostate cancer. Urol Oncol. 2016; 35(3):92-101. DOI: 10.1016/j.urolonc.2016.10.019. View

20.

Zhong J, Liu Y, Xu Q, Yu J, Zhang M . Inhibition of DIXDC1 by microRNA-1271 suppresses the proliferation and invasion of prostate cancer cells. Biochem Biophys Res Commun. 2017; 484(4):794-800. DOI: 10.1016/j.bbrc.2017.01.169. View